Suppr超能文献

瑞芬太尼和右美托咪定用于自发性脑出血患者的早期强化降压策略的效果:一项多中心、前瞻性、优效性、随机对照试验。

Effects of an Early Intensive Blood Pressure-lowering Strategy Using Remifentanil and Dexmedetomidine in Patients with Spontaneous Intracerebral Hemorrhage: A Multicenter, Prospective, Superiority, Randomized Controlled Trial.

机构信息

Department of Critical Care Medicine, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China.

Department of Intensive Care Unit, The First Hospital of Lanzhou University, Lanzhou, China.

出版信息

Anesthesiology. 2024 Jul 1;141(1):100-115. doi: 10.1097/ALN.0000000000004986.

Abstract

BACKGROUND

Although it has been established that elevated blood pressure and its variability worsen outcomes in spontaneous intracerebral hemorrhage, antihypertensives use during the acute phase still lacks robust evidence. A blood pressure-lowering regimen using remifentanil and dexmedetomidine might be a reasonable therapeutic option given their analgesic and antisympathetic effects. The objective of this superiority trial was to validate the efficacy and safety of this blood pressure-lowering strategy that uses remifentanil and dexmedetomidine in patients with acute intracerebral hemorrhage.

METHODS

In this multicenter, prospective, single-blinded, superiority randomized controlled trial, patients with intracerebral hemorrhage and systolic blood pressure (SBP) 150 mmHg or greater were randomly allocated to the intervention group (a preset protocol with a standard guideline management using remifentanil and dexmedetomidine) or the control group (standard guideline-based management) to receive blood pressure-lowering treatment. The primary outcome was the SBP control rate (less than 140 mmHg) at 1 h posttreatment initiation. Secondary outcomes included blood pressure variability, neurologic function, and clinical outcomes.

RESULTS

A total of 338 patients were allocated to the intervention (n = 167) or control group (n = 171). The SBP control rate at 1 h posttreatment initiation in the intervention group was higher than that in controls (101 of 161, 62.7% vs. 66 of 166, 39.8%; difference, 23.2%; 95% CI, 12.4 to 34.1%; P < 0.001). Analysis of secondary outcomes indicated that patients in the intervention group could effectively reduce agitation while achieving lighter sedation, but no improvement in clinical outcomes was observed. Regarding safety, the incidence of bradycardia and respiratory depression was higher in the intervention group.

CONCLUSIONS

Among intracerebral hemorrhage patients with a SBP 150 mmHg or greater, a preset protocol using a remifentanil and dexmedetomidine-based standard guideline management significantly increased the SBP control rate at 1 h posttreatment compared with the standard guideline-based management.

摘要

背景

虽然已经证实高血压及其变异性会使自发性脑出血的预后恶化,但在急性期使用降压药仍然缺乏有力的证据。由于瑞芬太尼和右美托咪定具有镇痛和抗交感作用,使用降压方案可能是一种合理的治疗选择。本优效性试验的目的是验证瑞芬太尼和右美托咪定降压方案在急性脑出血患者中的疗效和安全性。

方法

这是一项多中心、前瞻性、单盲、优效性随机对照试验,纳入收缩压(SBP)≥150mmHg 的脑出血患者,随机分配至干预组(采用瑞芬太尼和右美托咪定的预设方案标准指南管理)或对照组(基于标准指南的管理),以接受降压治疗。主要结局为治疗开始后 1h 的 SBP 控制率(<140mmHg)。次要结局包括血压变异性、神经功能和临床结局。

结果

共纳入 338 例患者,分配至干预组(n=167)或对照组(n=171)。治疗开始后 1h,干预组的 SBP 控制率高于对照组(161 例中的 101 例,62.7% vs. 166 例中的 66 例,39.8%;差异,23.2%;95%置信区间,12.4 至 34.1%;P<0.001)。次要结局分析表明,干预组患者可有效减少激越,同时实现更浅的镇静,但未观察到临床结局改善。安全性方面,干预组心动过缓和呼吸抑制的发生率更高。

结论

对于 SBP≥150mmHg 的脑出血患者,采用瑞芬太尼和右美托咪定的预设方案标准指南管理,与基于标准指南的管理相比,可显著提高治疗开始后 1h 的 SBP 控制率。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验